Company intelligence / Profile preview

Farlong Nutraceutical

Walnut, California, United Statesprweb.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Farlong has completed clinical trials on its ginseng extract showing positive effects on blood pressure and HDL-C, suggesting a potential for reducing cardiovascular disease risk. Its supplements are generally supported by clinical validation for safety and efficacy in wellness indications.

Therapeutic areas: NeurologyGastroenterologyOtherRheumatologyCardiovascular
Modalities: Herbal supplementPlant extractSmall molecule (plant-derived, not synthetic pharmaceuticals)
Industry: Food & Nutrition

Partnerships

City of Hope (research collaboration on anti-cancer and anti-diabetes herbal solutions)DirecTCM network (>30,000 healthcare providers distribution channel)

Beyond the preview

Go deeper on Farlong Nutraceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Farlong Nutraceutical.

Explore the full profile